Rayence Co. Ltd (228850) - Net Assets
Based on the latest financial reports, Rayence Co. Ltd (228850) has net assets worth ₩242.10 Billion KRW (≈ $164.07 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩271.97 Billion ≈ $184.31 Million USD) and total liabilities (₩29.87 Billion ≈ $20.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Rayence Co. Ltd to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩242.10 Billion |
| % of Total Assets | 89.02% |
| Annual Growth Rate | 14.74% |
| 5-Year Change | 18.34% |
| 10-Year Change | 43.49% |
| Growth Volatility | 51.62 |
Rayence Co. Ltd - Net Assets Trend (2015–2025)
This chart illustrates how Rayence Co. Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Rayence Co. Ltd market cap and net worth.
Annual Net Assets for Rayence Co. Ltd (2015–2025)
The table below shows the annual net assets of Rayence Co. Ltd from 2015 to 2025. Also explore Rayence Co. Ltd (228850) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩237.37 Billion ≈ $160.86 Million |
-2.98% |
| 2024-12-31 | ₩244.67 Billion ≈ $165.81 Million |
+1.61% |
| 2023-12-31 | ₩240.80 Billion ≈ $163.19 Million |
+7.14% |
| 2022-12-31 | ₩224.75 Billion ≈ $152.31 Million |
+12.05% |
| 2021-12-31 | ₩200.58 Billion ≈ $135.93 Million |
+6.59% |
| 2020-12-31 | ₩188.17 Billion ≈ $127.52 Million |
-3.15% |
| 2019-12-31 | ₩194.30 Billion ≈ $131.67 Million |
+6.84% |
| 2018-12-31 | ₩181.86 Billion ≈ $123.25 Million |
+2.96% |
| 2017-12-31 | ₩176.64 Billion ≈ $119.71 Million |
+6.78% |
| 2016-12-31 | ₩165.42 Billion ≈ $112.10 Million |
+175.62% |
| 2015-12-31 | ₩60.02 Billion ≈ $40.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Rayence Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 259.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩138.92 Billion | 58.62% |
| Other Components | ₩98.04 Billion | 41.38% |
| Total Equity | ₩236.96 Billion | 100.00% |
Rayence Co. Ltd Competitors by Market Cap
The table below lists competitors of Rayence Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Polaris Office Corp
KQ:041020
|
$77.86 Million |
|
Ares International Corp
TW:2471
|
$77.86 Million |
|
Da Ming International Holdings Limited
F:DM7
|
$77.88 Million |
|
Railcare Group AB (publ)
ST:RAIL
|
$77.88 Million |
|
Hyundai Livart Furniture Co Ltd
KO:079430
|
$77.83 Million |
|
Super Dragon Technology Co Ltd
TW:9955
|
$77.82 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
$77.76 Million |
|
PolyPid
NASDAQ:PYPD
|
$77.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rayence Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 244,396,535,960 to 236,957,034,890, a change of -7,439,501,070 (-3.0%).
- Net loss of 5,281,289,120 reduced equity.
- Dividend payments of 1,573,644,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.28 Billion | -2.23% |
| Dividends Paid | ₩1.57 Billion | -0.66% |
| Other Changes | ₩-584.57 Million | -0.25% |
| Total Change | ₩- | -3.04% |
Book Value vs Market Value Analysis
This analysis compares Rayence Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.72x to 0.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩10149.52 | ₩7300.00 | x |
| 2017-12-31 | ₩11015.10 | ₩7300.00 | x |
| 2018-12-31 | ₩11485.37 | ₩7300.00 | x |
| 2019-12-31 | ₩12346.92 | ₩7300.00 | x |
| 2020-12-31 | ₩11957.43 | ₩7300.00 | x |
| 2021-12-31 | ₩12745.95 | ₩7300.00 | x |
| 2022-12-31 | ₩14281.99 | ₩7300.00 | x |
| 2023-12-31 | ₩15265.30 | ₩7300.00 | x |
| 2024-12-31 | ₩15530.61 | ₩7300.00 | x |
| 2025-12-31 | ₩15057.86 | ₩7300.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rayence Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.60%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.10x
- Recent ROE (-2.23%) is below the historical average (7.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 24.13% | 16.72% | 0.92x | 1.57x | ₩8.48 Billion |
| 2016 | 8.91% | 14.98% | 0.52x | 1.15x | ₩-1.80 Billion |
| 2017 | 8.28% | 13.73% | 0.54x | 1.11x | ₩-3.04 Billion |
| 2018 | 8.65% | 13.51% | 0.58x | 1.11x | ₩-2.46 Billion |
| 2019 | 7.56% | 11.64% | 0.54x | 1.19x | ₩-4.74 Billion |
| 2020 | -1.02% | -1.89% | 0.45x | 1.19x | ₩-20.73 Billion |
| 2021 | 7.21% | 10.74% | 0.56x | 1.21x | ₩-5.60 Billion |
| 2022 | 9.81% | 14.98% | 0.56x | 1.17x | ₩-425.87 Million |
| 2023 | 8.16% | 13.71% | 0.52x | 1.16x | ₩-4.42 Billion |
| 2024 | 3.20% | 6.24% | 0.47x | 1.10x | ₩-16.61 Billion |
| 2025 | -2.23% | -4.60% | 0.44x | 1.10x | ₩-28.98 Billion |
Industry Comparison
This section compares Rayence Co. Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $339,148,185,798
- Average return on equity (ROE) among peers: -5.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rayence Co. Ltd (228850) | ₩242.10 Billion | 24.13% | 0.12x | $77.85 Million |
| Shinhung (004080) | $86.37 Billion | 3.67% | 0.52x | $89.01 Million |
| HansBiomed Corporation (042520) | $65.30 Billion | 6.15% | 0.41x | $159.83 Million |
| JVM Co. Ltd (054950) | $179.49 Billion | 14.62% | 0.43x | $180.31 Million |
| U&I Corporation (056090) | $57.68 Billion | -32.14% | 1.45x | $83.27 Million |
| Huvitz Co. Ltd (065510) | $65.32 Billion | 16.93% | 0.28x | $49.10 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $151.39 Million |
| Corentec Co Ltd (104540) | $24.09 Billion | -123.57% | 1.67x | $34.83 Million |
| SD Biosensor Inc (137310) | $2.34 Trillion | -21.91% | 0.39x | $499.36 Million |
| Hironic Co. Ltd (149980) | $41.60 Billion | 7.64% | 0.08x | $48.82 Million |
| Humasis Co. Ltd (205470) | $346.73 Billion | 52.67% | 0.35x | $217.40 Million |
About Rayence Co. Ltd
Rayence Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and sale of digital X-ray detector products for dental, medical, veterinary, and industrial sectors in South Korea, the United States, Mexico, China, and internationally. The company offers TFT/CMOS X-ray detectors for general radiography, C-arm/RF, mammography, and radiotherapy; and CMOS/Super IGZO TFT/a-… Read more